Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-091019
Filing Date
2025-06-27
Accepted
2025-06-27 17:06:29
Documents
1
Period of Report
2025-06-25

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 31577
  Complete submission text file 0000950170-25-091019.txt   33056
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Issuer) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121
Business Address
Aker Christopher Ray (Reporting) CIK: 0001762611 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35670 | Film No.: 251087633